Gene expression profile of epithelial–mesenchymal transition in tumours of patients with nonsmall cell lung cancer: the influence of COPD

Xia, Yingchen; Zha, Jianhua; Curull, Víctor; Sánchez-Font, Albert; Guitart, María; Rodríguez-Fuster, Alberto; Aguiló, Rafael; Barreiro, Esther

doi:10.1183/23120541.00105-2022

Cited by 3 publications

(2 citation statements)

References 42 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sample size for the study population was estimated using the GRANMO software, based on previous studies with similar recruitment approaches [10][11][12][13][14]. Assumptions of 80% power were chosen in all cases to detect differences of more than 20% in primary outcomes with a level of significance of p≤ 0.05 and a β-error of 0.2.…”

Section: Sample Size Estimationmentioning

confidence: 99%

“…Members of the BIOMEPOC group (alphabetical order): Mireia Admetlló 1,2 , Alvar Agustí 2,3 , Carlos Alvarez-Martínez 2,4 , Esther Barreiro 1,2 , Carme Casadevall 1,2 , Ferran Casals 10 , Robert Castelo 10 , Ady Castro-Acosta 2,4 , Rocío Córdova 2,9 , Borja G Cosío 2,9 , Rosa Faner 2,3 , Laura I Furlong 10,11 , Marian García 2,8 , Joaquim Gea 1,2 , José G. González-García 1,2 , Carmen Hernández-Carcereny 2,3 , José Luis López-Campos 2,6 , Eduardo Márquez 2,6 , Eduard Monsó 2,8 , Concepción Montón 2,8 , Miren Josune Ormaza 2,8 , Alexandre Palou 2,9 , Sergi Pascual 1,2 , Germán Peces- Barba 2,7 , Pau Puigdevall 10 , Ferran Sanz 10,11 , Luis Seijó 2,5 , Montserrat Torà 10,12 , Yolanda Torralba 2,3 , Carles Vilaplana 13 ----------------------------------...…”

Section: Addendumunclassified

See 1 more Smart Citation

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

Enríquez-Rodríguez,

Casadevall,

Faner

et al. 2024

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

BackgroundSome patients with chronic obstructive pulmonary disease (COPD) suffer frequent exacerbations (FE). We hypothesized that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE).ObjectivesTo contrast the systemic proteomic profile in FEversusNFE. As a reference, we also determined the systemic proteomic profile of healthy controls (HC) and COPD patients during an actual episode of exacerbation (AE).MethodsIn the analysis we included 40 clinically stable COPD patients (20 FE and 20 NFE), 20 HC and 10 AE patients. Their plasma samples were analysed by combining two complementary proteomic approaches: label-free liquid chromatography-tandem mass spectrometry and multiplex immunoassays. Gene Ontology annotation, pathway enrichment and network analyses were used to investigate molecular pathways associated with differentially abundant proteins-peptides (DAPs).ResultsCompared with HC, we identified 40 DAPs in FE, 10 in NFE and 63 in AE. Also compared to HC, pathway functional and protein-protein network analyses revealed dysregulation of inflammatory responses involving innate and antibody-mediated immunity in COPD, particularly in the FE group, as well as during an AE episode. Besides, we only identified alterations in the complement and coagulation cascades in AE.ConclusionThere are specific plasma proteome profiles associated with FE, which are partially shared with findings observed during AE, albeit others are uniquely present during the actual episode of AE.

show abstract

Section: Sample Size Estimationmentioning

confidence: 99%

Section: Addendumunclassified

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

Enríquez-Rodríguez,

Casadevall,

Faner

et al. 2024

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

show abstract

International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

Zhou¹,

Qin²,

Zhao³

et al. 2023

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

Background Lung cancer combined by chronic obstructive pulmonary disease (LC-COPD) is a common comorbidity and their interaction with each other poses significant clinical challenges. However, there is a lack of well-established consensus on the diagnosis and treatment of LC-COPD. Methods A panel of experts, comprising specialists in oncology, respiratory medicine, radiology, interventional medicine, and thoracic surgery, was convened. The panel was presented with a comprehensive review of the current evidence pertaining to LC-COPD. After thorough discussions, the panel reached a consensus on 17 recommendations with over 70% agreement in voting to enhance the management of LC-COPD and optimize the care of these patients. Results The 17 statements focused on pathogenic mechanisms (n=2), general strategies (n=4), and clinical application in COPD (n=2) and lung cancer (n=9) were developed and modified. These statements provide guidance on early screening and treatment selection of LC-COPD, the interplay of lung cancer and COPD on treatment, and considerations during treatment. This consensus also emphasizes patient-centered and personalized treatment in the management of LC-COPD. Conclusions The consensus highlights the need for concurrent treatment for both lung cancer and COPD in LC-COPD patients, while being mindful of the mutual influence of the two conditions on treatment and monitoring for adverse reactions.

show abstract

Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential

Abdul Manap,

Ngwenya,

Kalai Selvan

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer is frequently detected in an advanced stage and has an unfavourable prognosis. Conventional therapies are ineffective for the treatment of metastatic lung cancer. While certain molecular targets have been identified as having a positive response, the absence of appropriate drug carriers prevents their effective utilization. Lung cancer cell-derived exosomes (LCCDEs) have gained attention for their involvement in the development of cancer, as well as their potential for use in diagnosing, treating, and predicting the outcome of lung cancer. This is due to their biological roles and their inherent ability to transport biomolecules from the donor cells. Lung cancer-associated cell-derived extracellular vesicles (LCCDEVs) have the ability to enhance cell proliferation and metastasis, influence angiogenesis, regulate immune responses against tumours during the development of lung cancer, control drug resistance in lung cancer treatment, and are increasingly recognised as a crucial element in liquid biopsy evaluations for the detection of lung cancer. Therapeutic exosomes, which possess inherent intercellular communication capabilities, are increasingly recognised as effective vehicles for targeted drug delivery in precision medicine for tumours. This is due to their exceptional biocompatibility, minimal immunogenicity, low toxicity, prolonged circulation in the bloodstream, biodegradability, and ability to traverse different biological barriers. Currently, multiple studies are being conducted to create new means of diagnosing and predicting outcomes using LCCDEs, as well as to develop techniques for utilizing exosomes as effective carriers for medication delivery. This paper provides an overview of the current state of lung cancer and the wide range of applications of LCCDEs. The encouraging findings and technologies suggest that the utilization of LCCDEs holds promise for the clinical treatment of lung cancer patients.

show abstract

Gene expression profile of epithelial–mesenchymal transition in tumours of patients with nonsmall cell lung cancer: the influence of COPD

Cited by 3 publications

References 42 publications

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential

Contact Info

Product

Resources

About